Educational research on US and Indian equities, ETFs, mutual funds and crypto, with screeners and a free investing academy.
All data is for educational purposes only and should not be considered investment advice.
Equiscale is operated by Syntellia LLC, a Delaware limited liability company.
© 2026 Syntellia LLC. All rights reserved.
Lumexa Imaging Holdings, Inc. owns and operates diagnostic imaging centres in the United States. The company provides outpatient medical imaging services, such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) services, as well as X-ray, ultrasound, and mammography diagnostic and screening imaging services. Lumexa Imaging Holdings, Inc. was founded in 2018 and is based in Raleigh, North Carolina.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 3 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.0B | $142M | $-47M | $-6M | -8.0% | 7.8% | -49.9% |
| 2024 | $949M | $114M | $-94M | $13M | -58.2% | 1.4% | -23.0% |
| 2023 | $936M | $95M | $-122M | $14M | -61.6% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2025 |
|---|---|
| Total Revenue | 1,023.08 |
| Operating Revenue | 1,023.08 |
| Cost Of Revenue | 865.52 |
| Gross Profit | 157.56 |
| Operating Expense | 130.83 |
| Selling General And Administration | 90.45 |
| Total Expenses | 996.35 |
| Operating Income | 26.73 |
| Total Operating Income As Reported | 97.90 |
| EBITDA | 141.71 |
| Normalized EBITDA | 156.13 |
| EBIT | 86.32 |
| Interest Expense | 118.54 |
| Net Interest Income | -118.54 |
| Other Non Operating Income Expenses | 1.87 |
| Other Income Expense | 59.59 |
| Interest Expense Non Operating | 118.54 |
| Net Non Operating Interest Income Expense | -118.54 |
| Pretax Income | -32.22 |
| Tax Provision | 14.88 |
| Tax Rate For Calcs | 0 |
| Tax Effect Of Unusual Items | -3.03 |
| Net Income Continuous Operations | -47.10 |
| Net Income From Continuing And Discontinued Operation | -47.10 |
| Net Income From Continuing Operation Net Minority Interest | -47.10 |
| Net Income | -47.10 |
| Net Income Common Stockholders | -47.10 |
| Net Income Including Noncontrolling Interests | -47.10 |
| Normalized Income | -35.71 |
| Diluted NI Availto Com Stockholders | -47.10 |
| Basic Average Shares | 70.98 |
| Diluted Average Shares | 70.98 |
| Reconciled Depreciation | 55.39 |
| Reconciled Cost Of Revenue | 850.51 |
| Total Unusual Items | -14.42 |
| Total Unusual Items Excluding Goodwill | -14.42 |
| Special Income Charges | -14.42 |
| Other Special Charges | 13.45 |
| Impairment Of Capital Assets | 0 |
| Depreciation Amortization Depletion Income Statement | 40.38 |
| Depreciation And Amortization In Income Statement | 40.38 |
| General And Administrative Expense | 90.45 |
| Other Gand A | 90.45 |
| Gain On Sale Of Ppe | -0.97 |
| Earnings From Equity Interest | 72.14 |
| Amortization | 6.50 |
| Amortization Of Intangibles Income Statement | 6.50 |
| Depreciation Income Statement | 33.88 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Lumexa Imaging Holdings, Inc.this co. | LMRI | $792M | -16.81 | 1.35 | -8.0% | 11.96 |
| Amphastar Pharmaceuticals, Inc. | AMPH | $825M | 8.41 | 1.05 | 12.4% | 6.17 |
| Sana Biotechnology, Inc. | SANA | $824M | -3.37 | 5.12 | -151.8% | -4.31 |
| Replimune Group, Inc. | REPL | $815M | -3.30 | 1.96 | -59.5% | -3.31 |
| Esperion Therapeutics, Inc. | ESPR |
| $806M |
| - |
| - |
| 7.5% |
| 13.94 |
| Eton Pharmaceuticals, Inc. | ETON | $792M | -172.06 | 30.27 | -17.6% | 248.97 |
| Phathom Pharmaceuticals, Inc. | PHAT | $786M | -3.55 | -1.79 | 50.5% | -5.69 |
| Kura Oncology, Inc. | KURA | $779M | - | 4.47 | -160.0% | - |
| Geron Corporation | GERN | $776M | -9.30 | 3.44 | -37.0% | -16.53 |
| Peer Median | - | -3.46 | 3.44 | -27.3% | -3.31 | |